drugset / Trial / NCT05378646

Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis

NCT05378646

Phase 3 Completed 30 enrolled SPP Pharmaclon Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purposes of the study are to evaluate the effectiveness of Ingaron in the complex therapy of chronic prostatitis, to assess the safety of using Ingaron in patients with chronic prostatitis.

Timeline

Start
2009-01-29
Primary completion
2009-12-31
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject interferon gamma Protein / enzyme biologic 500000 iu Subcutaneous

Indications